Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oncopeptides ABCHIX:ONCOS 46 3-Year EBITDA Growth Rate is 27.70% as of Mar. 2026. GuruFocus rates CHIX:ONCOS with a GF Score™ of 46/100 and a GF Value™ of kr5.80 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,135 Biotechnology companies, Oncopeptides AB ranks better than 63.52% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 27.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 45.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 4.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Oncopeptides AB was 53.40% per year. The lowest was -95.60% per year. And the median was -25.00% per year.
Oncopeptides AB (CHIX:ONCOs) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Oncopeptides AB 3-Year EBITDA Growth Rate Related Terms
CHIX:ONCOS vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Oncopeptides AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncopeptides AB 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncopeptides AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Oncopeptides AB's 3-Year EBITDA Growth Rate falls into.
Oncopeptides AB 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 27.70% mean?
Oncopeptides AB (CHIX:ONCOS) has a 3-Year EBITDA Growth Rate of 27.70% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Oncopeptides AB and its competitors. According to the industry distribution chart, Oncopeptides AB ranks #414 out of 1135 companies in the Biotechnology industry, placing it in the top 36.5%.
Is Oncopeptides AB's 3-Year EBITDA Growth Rate too high?
Oncopeptides AB's current 3-Year EBITDA Growth Rate is 27.70%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Oncopeptides AB's value of 27.70% is 85.9% above this industry median. Based on the distribution chart, Oncopeptides AB ranks #414 out of 1135 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Oncopeptides AB has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncopeptides AB's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncopeptides AB ranks #414 out of 1135 companies for 3-Year EBITDA Growth Rate. This puts Oncopeptides AB in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. Oncopeptides AB's value of 27.70% is 85.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,135 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncopeptides AB's current 3-Year EBITDA Growth Rate of 27.70% is 85.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Oncopeptides AB and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncopeptides AB's current 3-Year EBITDA Growth Rate is 27.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncopeptides AB stock overvalued right now?
Based on GuruFocus' analysis, Oncopeptides AB (CHIX:ONCOS) is currently considered Possible Value Trap. The stock's GF Value™ is kr5.80, compared to a current price of kr1.72 — trading 70.3% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 27.70% and 85.9% above the Biotechnology industry median of 14.90. Oncopeptides AB's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Oncopeptides AB (CHIX:ONCOS), the current 3-Year EBITDA Growth Rate is 27.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncopeptides AB (CHIX:ONCOS) Overvalued in 2026?
Based on GuruFocus' analysis, Oncopeptides AB stock appears to be undervalued.
The current stock price of kr1.72 is trading 70.3% below its estimated GF Value™ of kr5.80.
GuruFocus considers Oncopeptides AB to be Possible Value Trap.
Key valuation signals for CHIX:ONCOS:
3-Year EBITDA Growth Rate: 27.70%
GF Value™: kr5.80 vs. price of kr1.72 (70.3% below fair value)
Industry Position: 85.9% above the Biotechnology median (#414 of 1135)
No single metric tells the full story. See the CHIX:ONCOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.
46GF Score
Get the complete analysis for CHIX:ONCOS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ONCOS has been successfully added to your 
